HT
TBPH icon

Headlands Technologies’s Theravance Biopharma TBPH Stock Holding History

Headlands Technologies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,471
Closed -$170K – 982
2026
Q1 		$170K Buy
+10,471
New +$185K 0.02% 613

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Headlands Technologies's TBPH Position: Q2 2026 in Review

Headlands Technologies sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 10,471 shares — an estimated $170K sold.

Headlands Technologies first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $170K in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Headlands Technologies reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 10,471 Theravance Biopharma shares in Q2 2026, an estimated $170K.
  • Headlands Technologies first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
  • Headlands Technologies's Theravance Biopharma position peaked at $170K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.